MRSA Susceptible MICs for Daptomycin
The daptomycin susceptibility breakpoint for MRSA is ≤1 µg/mL 1.
Susceptibility Breakpoint Definition
According to the FDA-approved drug label and IDSA guidelines, S. aureus isolates (including MRSA) with daptomycin MICs ≤1 µg/mL are considered susceptible 1. This is the established Clinical and Laboratory Standards Institute (CLSI) breakpoint that defines susceptibility.
Clinical Implications of MIC Values
MIC ≤1 µg/mL (Susceptible)
- All MRSA isolates with MICs in this range are considered susceptible and appropriate for daptomycin therapy
- Multiple studies confirm that MICs typically range from 0.047-1 µg/mL for MRSA isolates 2, 3, 4
- The MIC₉₀ values across various studies consistently fall at 0.5-1 µg/mL 4, 5
MIC >1 µg/mL (Non-susceptible)
- Isolates with daptomycin MICs >1 µg/mL are considered non-susceptible 1
- These strains have emerged during therapy and are associated with treatment failure 1
- Persistent bacteremia and clinical failures with daptomycin have been specifically associated with daptomycin MICs >1 µg/mL 1
Important Clinical Caveats
Testing Method Variability
The E-test method tends to report slightly higher MIC values compared to reference broth microdilution 1. This means:
- An E-test result showing MIC of 1.5 µg/mL might actually represent a lower true MIC by broth microdilution
- However, for clinical decision-making, use the reported MIC value from your laboratory's method
Dosing Considerations Based on MIC
When treating serious MRSA infections with isolates at the upper end of susceptibility (MIC approaching 1 µg/mL):
- Consider high-dose daptomycin (10 mg/kg/day) rather than standard dosing (6 mg/kg/day) 1
- High-dose daptomycin may be effective even for strains with MIC of 2 µg/mL in complicated bacteremia 1
- Combination therapy with another agent should be considered for persistent bacteremia 1
Cross-Resistance Warning
Prior vancomycin exposure and elevated vancomycin MICs have been associated with increases in daptomycin MICs, suggesting possible cross-resistance 1. Monitor clinical response carefully in patients with vancomycin treatment failures.